{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T22:29:12Z","timestamp":1766788152118,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK057136"],"award-info":[{"award-number":["DK057136"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT173471"],"award-info":[{"award-number":["PJT173471"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Disease Risk in Diabetes (ACCORD) participants with the haptoglobin (Hp) 2-2 phenotype only. It remains unknown whether Hp phenotype modifies the effect of an intensive lifestyle intervention (ILI) on CAD in type 2 diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Haptoglobin phenotype was measured in 4542 samples from the Action for Health in Diabetes (Look AHEAD) study. Cox regression models assessed the effect of ILI (focused on weight loss from caloric restriction and physical activity) versus diabetes support and education (DSE) on CAD events in each phenotype group, and within pre-specified subgroups including race\/ethnicity, sex, history of cardiovascular disease, diabetes medication use, and diabetes duration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>1590 (35%) participants had the Hp2-2 phenotype. The ILI did not lower glycated hemoglobin (%HbA1c) to\u2009&lt;\u20096.5% in either phenotype, with a peak significant difference between treatment arms of 0.5% [non-Hp2-2] and 0.6% [Hp2-2]. The cumulative CAD incidence was 13.4% and 13.8% in the DSE arm and 12.2% and 13.6% in the ILI arm for non-Hp2-2 and Hp2-2 groups, respectively. Compared to DSE, the ILI was not associated with CAD among participants without (HR\u2009=\u20090.95, 95% CI 0.78\u20131.17) or with (0.89, 0.68\u20131.19) the Hp2-2 phenotype (p-interaction between Hp phenotype and ILI\u2009=\u20090.58). After Bonferroni correction, there were no significant results among any subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Hp phenotype did not modify the effect of the weight loss ILI on risk of CAD in Look AHEAD, potentially because it did not substantially impact glycemic control among participants with or without the Hp2-2 phenotype. Further research is needed to determine if these results are conclusive.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-024-02164-8","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T13:02:09Z","timestamp":1708779729000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Intensive lifestyle intervention in type 2 diabetes and risk of incident coronary artery disease for the common haptoglobin phenotypes: the Look AHEAD study"],"prefix":"10.1186","volume":"23","author":[{"given":"Rachel A.","family":"Warren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Bancks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allie S.","family":"Carew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Sapp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Bahnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cora E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric B.","family":"Rimm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Espeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leah E.","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"2164_CR1","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"The Emerging Risk Factors Collaboration","year":"2010","unstructured":"The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215\u201322.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"2164_CR2","first-page":"S1","volume":"42","author":"Diabetes Canada Clinical Practice Guidelines Expert Committee","year":"2018","unstructured":"Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabet. 2018;42(Suppl 1):S1-325.","journal-title":"Can J Diabet"},{"key":"2164_CR3","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.2337\/dc22-S008","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","unstructured":"American Diabetes Association Professional Practice Committee. Obesity and weight management for the prevention and treatment of type 2 diabetes: standards of medical care in diabetes\u20142022. Diabet Care. 2022;45:S113-24.","journal-title":"Diabet Care"},{"issue":"2","key":"2164_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa1212914","volume":"369","author":"The Look AHEAD Research Group","year":"2013","unstructured":"The Look AHEAD Research Group. Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. N Engl J Med. 2013;369(2):145\u201354.","journal-title":"N Engl J Med"},{"issue":"5","key":"2164_CR5","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S0197-2456(03)00064-3","volume":"24","author":"The Look AHEAD Research Group","year":"2003","unstructured":"The Look AHEAD Research Group. Look AHEAD (action for health in diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials. 2003;24(5):610\u201328.","journal-title":"Control Clin Trials"},{"issue":"12","key":"2164_CR6","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1161\/01.RES.0000251741.65179.56","volume":"99","author":"R Asleh","year":"2006","unstructured":"Asleh R, Miller-Lotan Milman U, Miller B, Shapira C, Hayek T, et al. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res. 2006;99(12):1419\u201325.","journal-title":"Circ Res"},{"issue":"10","key":"2164_CR7","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.2337\/db08-0450","volume":"57","author":"R Asleh","year":"2008","unstructured":"Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, et al. Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2\u20132 genotype. Diabetes. 2008;57(10):2794\u2013800.","journal-title":"Diabetes"},{"issue":"7","key":"2164_CR8","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jacc.2012.09.063","volume":"61","author":"LE Cahill","year":"2013","unstructured":"Cahill LE, Levy AP, Chiuve SE, Jensen MK, Wang H, Shara NM, et al. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol. 2013;61(7):728\u201337.","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"2164_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.jacc.2015.07.076","volume":"66","author":"LE Cahill","year":"2015","unstructured":"Cahill LE, Jensen MK, Chiuve SE, Shalom H, Pai JK, Flint AJ, et al. The risk of coronary heart disease associated with glycosylated hemoglobin of 6.5% or greater is pronounced in the haptoglobin 2\u20132 genotype. J Am Coll Cardiol. 2015;66(16):1791\u20139.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2164_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/j.1751-553X.2007.00898.x","volume":"29","author":"K Carter","year":"2007","unstructured":"Carter K, Worwood M. Haptoglobin: a review of the major allele frequencies worldwide and their association with diseases. Int J Lab Hematol. 2007;29(2):92\u2013110.","journal-title":"Int J Lab Hematol"},{"issue":"11","key":"2164_CR11","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1161\/01.RES.0000076889.23082.F1","volume":"92","author":"R Asleh","year":"2003","unstructured":"Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res. 2003;92(11):1193\u2013200.","journal-title":"Circ Res"},{"issue":"4","key":"2164_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/01.RES.0000156653.05853.b9","volume":"96","author":"R Asleh","year":"2005","unstructured":"Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype\u2013 and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96(4):435\u201341.","journal-title":"Circ Res"},{"issue":"4","key":"2164_CR13","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1161\/ATVBAHA.118.312232","volume":"39","author":"R Asleh","year":"2019","unstructured":"Asleh R, Levy AP, Levy NS, Asleh A, Goldenstein H, Segol I, et al. Haptoglobin phenotype is associated with high-density lipoprotein-bound hemoglobin content and coronary endothelial dysfunction in patients with mild nonobstructive coronary artery disease. Arterioscler Thromb Vasc Biol. 2019;39(4):774\u201386.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"24","key":"2164_CR14","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"The ACCORD Study Group","year":"2008","unstructured":"The ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545\u201359.","journal-title":"N Engl J Med"},{"issue":"2","key":"2164_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","volume":"360","author":"W Duckworth","year":"2009","unstructured":"Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"5","key":"2164_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacc.2019.11.051","volume":"75","author":"AS Carew","year":"2020","unstructured":"Carew AS, Levy AP, Ginsberg HN, Coca S, Lache O, Ransom T, et al. Haptoglobin phenotype modifies the influence of intensive glycemic control on cardiovascular outcomes. J Am Coll Cardiol. 2020;75(5):512\u201321.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2164_CR17","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1515\/cclm-2013-0018","volume":"51","author":"NS Levy","year":"2013","unstructured":"Levy NS, Vardi M, Blum S, Miller-Lotan R, Afinbinder Y, Cleary PA, et al. An enzyme linked immunosorbent assay (ELISA) for the determination of the human haptoglobin phenotype. Clin Chem Lab Med CCLM. 2013;51(8):1615\u201322.","journal-title":"Clin Chem Lab Med CCLM"},{"issue":"2","key":"2164_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/ars.2009.2793","volume":"12","author":"AP Levy","year":"2010","unstructured":"Levy AP, Asleh R, Blum S, Levy NS, Miller-Lotan R, Kalet-Litman S, et al. Haptoglobin: basic and clinical aspects. Antioxid Redox Signal. 2010;12(2):293\u2013304.","journal-title":"Antioxid Redox Signal"},{"issue":"3","key":"2164_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.2174\/156720208785425675","volume":"5","author":"J Staals","year":"2008","unstructured":"Staals J, Pieters B, Knottnerus IL, Rouhl RP, VOLodder RJJ. Haptoglobin polymorphism and lacunar stroke. Curr Neurovasc Res. 2008;5(3):153\u20138.","journal-title":"Curr Neurovasc Res"},{"issue":"5","key":"2164_CR20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1479164114539713","volume":"11","author":"T Costacou","year":"2014","unstructured":"Costacou T, Secrest AM, Ferrell RE, Orchard TJ. Haptoglobin genotype and cerebrovascular disease incidence in type 1 diabetes. Diab Vasc Dis Res. 2014;11(5):335\u201342.","journal-title":"Diab Vasc Dis Res"},{"issue":"2","key":"2164_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0022-2836(84)90342-5","volume":"174","author":"JC Wejman","year":"1984","unstructured":"Wejman JC, Hovsepian D, Wall JS, Hainfeld JF, Greer J. Structure and assembly of haptoglobin polymers by electron microscopy. J Mol Biol. 1984;174(2):343\u201368.","journal-title":"J Mol Biol"},{"issue":"2","key":"2164_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00592-015-0770-8","volume":"53","author":"T Costacou","year":"2015","unstructured":"Costacou T, Levy AP, Miller RG, Farbstein D, de la Vega R, Snell-Bergeon J, et al. Effect of vitamin E supplementation on HDL function by haptoglobin genotype in type 1 diabetes: results from the HapE randomized crossover pilot trial. Acta Diabetol. 2015;53(2):243\u201350.","journal-title":"Acta Diabetol"},{"key":"2164_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"P Austin","year":"2016","unstructured":"Austin P, Lee D, Fine JP. Introduction to the analysis of survival data in the presence of competing risks. Circulation. 2016;133:601\u20139.","journal-title":"Circulation"},{"issue":"2","key":"2164_CR24","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/aje\/kwp107","volume":"170","author":"B Lau","year":"2009","unstructured":"Lau B, Cole SR, Gange SJ. Competing Risk Regression Models for Epidemiologic Data. Am J Epidemiol. 2009;170(2):244\u201356.","journal-title":"Am J Epidemiol"},{"key":"2164_CR25","unstructured":"National Insitutes of Health. National Institues of Heath Office of Research on Women\u2019s Health. NIH Policy on Sex as a Biological Variable. Available from: https:\/\/orwh.od.nih.gov\/sex-gender\/nih-policy-sex-biological-variable"},{"key":"2164_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2337\/dc23-S006","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 6. glycemic targets: standards of care in diabetes\u20142023. Diabet Care. 2023;46:97\u2013110.","journal-title":"Diabet Care"},{"issue":"1","key":"2164_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/EDE.0b013e318230e861","volume":"23","author":"J Weuve","year":"2012","unstructured":"Weuve J, Tchetgen EJ, Glymour MM, Beck TL, Aggarwal NT, Wilson RS, et al. Accounting for bias due to selective attrition: the example of smoking and cognitive decline. Epidemiology. 2012;23(1):119\u201328.","journal-title":"Epidemiology"},{"key":"2164_CR28","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2337\/dc23-0760","volume":"46","author":"L Cahill","year":"2023","unstructured":"Cahill L, Warren R, Carew A, Levy A, Ginsberg H, Sapp J, et al. The relationship between time-varying achieved hba1c and risk of coronary events depends on haptoglobin phenotype among white and black ACCORD participants. Diabet Care. 2023;46:1941\u20138.","journal-title":"Diabet Care"},{"issue":"1","key":"2164_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.107.149435","volume":"101","author":"AP Levy","year":"2007","unstructured":"Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R, et al. Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 Genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res. 2007;101(1):106\u201310.","journal-title":"Circ Res"},{"issue":"13","key":"2164_CR30","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1182\/blood.V98.13.3693","volume":"98","author":"M Melamed-Frank","year":"2001","unstructured":"Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 2001;98(13):3693\u20138.","journal-title":"Blood"},{"issue":"1","key":"2164_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2006.04.032","volume":"191","author":"J Guetta","year":"2007","unstructured":"Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP. Haptoglobin genotype modulates the balance of Th1\/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis. 2007;191(1):48\u201353.","journal-title":"Atherosclerosis"},{"issue":"10","key":"2164_CR32","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/clinchem\/42.10.1589","volume":"42","author":"MR Langlois","year":"1996","unstructured":"Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42(10):1589\u201300.","journal-title":"Clin Chem"},{"issue":"4","key":"2164_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1161\/01.RES.0000156653.05853.b9","volume":"96","author":"R Asleh","year":"2005","unstructured":"Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res. 2005;96(4):435\u201341.","journal-title":"Circ Res"},{"issue":"13","key":"2164_CR34","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1182\/blood.V98.13.3693","volume":"98","author":"M Melamed-Frank","year":"2001","unstructured":"Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, et al. Structure-function analysis of the antioxidant properties of haptoglobin. Blood. 2001;98(13):3693\u20138.","journal-title":"Blood"},{"issue":"1","key":"2164_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.atherosclerosis.2006.04.032","volume":"191","author":"J Guetta","year":"2007","unstructured":"Guetta J, Strauss M, Levy NS, Fahoum L, Levy AP. Haptoglobin genotype modulates the balance of Th1\/Th2 cytokines produced by macrophages exposed to free hemoglobin. Atherosclerosis. 2007;191(1):48\u201353.","journal-title":"Atherosclerosis"},{"issue":"1","key":"2164_CR36","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.clnu.2019.01.019","volume":"39","author":"KY Tang","year":"2020","unstructured":"Tang KY, Huang SY, Cheng TM, Bai CH, Chang JS. Haptoglobin phenotype influences the effectiveness of diet-induced weight loss in middle-age abdominally obese women with metabolic abnormalities. Clin Nutr. 2020;39(1):225\u201333.","journal-title":"Clin Nutr"},{"key":"2164_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110024","author":"MI Madkour","year":"2022","unstructured":"Madkour MI, Hassan RE, Sherif NM, Awadallah S, Abdelrahim DN, Jahrami H, et al. Haptoglobin polymorphism modulates cardiometabolic impacts of four consecutive weeks, dawn to sunset Ramadan intermittent fasting among subjects with overweight\/obesity. Diabet Res Clin Pract. 2022. https:\/\/doi.org\/10.1016\/j.diabres.2022.110024.","journal-title":"Diabet Res Clin Pract"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02164-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-024-02164-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-024-02164-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T13:02:29Z","timestamp":1708779749000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-024-02164-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2164"],"URL":"https:\/\/doi.org\/10.1186\/s12933-024-02164-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"type":"electronic","value":"1475-2840"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"10 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Each participating center obtained ethical approval, and all participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}